MarketInOut Stock Screener Log In | Sign Up
 

Scholar Rock Holding Corp

NASDAQ • Healthcare • Biotechnology • Quote as of 05/22/2026
Scholar Rock Holding Corp stock price and volume chart

Company Profile

IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization5,654.7 mln
Float91.86 mln
Earnings Date08/12/2026

Piotroski F-Score

1 / 9
Very weak

1-Year Forecast

59.00
Attractive

Relative Strength

46 / 100
Slightly lagging

Debt / Equity

0.75
Moderate leverage

ROE

-156
Deeply negative

Dividend Yield

0.00%
No dividend

Business Description

Scholar Rock is a biopharmaceutical company based in Cambridge, Massachusetts, focused on treating rare and serious muscle and nerve diseases, including spinal muscular atrophy. The company has built a drug discovery platform that targets specific proteins responsible for muscle loss and disease progression, which has produced several drug candidates at various stages of clinical testing. Its leading medicine, Apitegromab, is currently in clinical trials for spinal muscular atrophy, while other compounds are being studied for conditions such as solid tumors resistant to standard therapies, fibrotic diseases, and certain forms of anemia. Founded in 2012, Scholar Rock continues to expand its research pipeline with the goal of addressing conditions that currently have few or no effective treatment options.

Key Fundamentals

EPS-3.45
ROE-156
ROIC-1,563
ROA-97.37
EBITDA, mln-400
EV / EBITDA-13.82
EV / EBIT-13.76

Financial Strength

Piotroski F-Score 1 / 9
1-Year Target Price59.00
Short Ratio9.22
Short % of Float15.68

Price Performance & Relative Strength

Period Price Performance Relative Strength
1 Week -2.47% 18 / 100   
1 Month 1.37% 57 / 100   
2 Months 4.68% 64 / 100   
6 Months 21.26% 78 / 100   
1 Year 56.67% 84 / 100   



Disclaimer - Privacy Policy - Terms Of Service - Cookie Use Policy - FAQ - Contact Us